| Typicality: | 0.207 |
| Saliency: | 0.105 |
| with abatacept | 2 | other |
| in abatacept plus methotrexate group | 2 | location |
| improvement → be observed at → 12 months | 3 |
| improvement → be seen at → 12 and 24 months | 3 |
| negative | neutral | positive |
| 0.002 | 0.227 | 0.771 |
| Raw frequency | 6 |
| Normalized frequency | 0.105 |
| Modifier score | 0.500 |
| Perplexity | 66.352 |